drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody biologic
drug_description
A humanized monoclonal antibody targeting IL-5 receptor alpha (IL-5Rα) on eosinophils and basophils, inducing rapid cytotoxic depletion to reduce eosinophilic airway inflammation in severe asthma; modulates type-2 inflammatory pathways (IL-5, IL-4, IL-13) including the IL-13/FeNO axis, with potential effects on ILC2s, epithelial cells, macrophages, mast cells, and airway smooth muscle, and exploratory restoration of antiviral responses.
nci_thesaurus_concept_id
C88594
nci_thesaurus_preferred_term
Benralizumab
nci_thesaurus_definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated humanized monoclonal antibody that binds IL-5 receptor alpha (IL-5Rα) on eosinophils and basophils and engages FcγRIIIa to drive potent ADCC, causing rapid depletion of these cells and consequent suppression of eosinophilic/type‑2 inflammation (IL‑5/IL‑4/IL‑13 pathways) in severe asthma.
drug_name
Benralizumab
nct_id_drug_ref
NCT05847452